Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 15/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12906161 | 0.72 | NOTUM (0.59) | NOTUMTSHRMAPTTLR8KDM4E | |
| SCHEMBL13484029 | 0.67 | NOTUM (0.46) | NOTUMTSHRMAPTKDM4EALDH1A1 | |
| SCHEMBL15611162 | 0.67 | NOTUM (0.39) | NOTUMTSHRMAPTTLR8KDM4E | |
| SCHEMBL12446805 | 0.65 | NOTUM (0.66) | NOTUMTLR8KDM4E | |
| SCHEMBL17694561 | 0.64 | NOTUM (0.78) | NOTUMTSHRMAPTTLR8KDM4E | |
| SCHEMBL28271180 | 0.64 | ENPP3 (0.31) | — | |
| SCHEMBL539177 | 0.64 | NOTUM (0.41) | NOTUMTSHRALDH1A1LMNA | |
| SCHEMBL2241254 | 0.64 | NOTUM (0.41) | NOTUMTSHRMAPTTLR8KDM4E | |
| SCHEMBL27009014 | 0.64 | NOTUM (0.41) | NOTUMTSHRMAPTTLR8ALDH1A1 | |
| SCHEMBL5959922 | 0.63 | NOTUM (0.39) | NOTUMTSHRMAPTTLR8KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9949979-B2 | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG (CH) | 2018-04-24 | — | — | US | claimed |
| EP-2790705-B1 | USE OF INHIBITORS OF THE ACTIVITY OR FUNCTION OF PI3K | NOVARTIS AG (CH) | 2017-12-06 | — | — | EP | claimed |
| EP-2590974-B1 | TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2014-05-21 | — | — | EP | claimed |
| US-8653092-B2 | Tetrahydro-pyrido-pyrimidine derivatives | NOVARTIS AG (CH) | 2014-02-18 | — | — | US | claimed |
| CN-1674899-A | Use of IkappaB-kinase inhibitors in pain therapy | AVENTIS PHARMA GMBH (DE) | 2005-09-28 | — | — | CN | claimed |
| CN-1675196-A | Indole derivatives or benzimidazole derivatives for modulating IKB kinase | AVENTIS PHARMA GMBH (DE) | 2005-09-28 | — | — | CN | claimed |
| EP-2790705-B1 | USE OF INHIBITORS OF THE ACTIVITY OR FUNCTION OF PI3K | NOVARTIS AG (CH) | 2017-12-06 | — | — | EP | disclosed |
| US-20160052912-A1 | DIAMINOHETEROARYL SUBSTITUTED INDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-25 | — | — | US | disclosed |
| US-9265763-B2 | — | — | 2016-02-23 | — | — | US | disclosed |
| EP-2616465-B1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2015-11-04 | — | — | EP | disclosed |
| US-8987286-B2 | Substituted pyrimido[1,2-b]indazoles and their use as modulators of the Pi3K/Akt pathway | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| EP-2590974-B1 | TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2014-05-21 | — | — | EP | disclosed |
| US-20140051676-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-02-20 | — | — | US | disclosed |
| US-8653092-B2 | Tetrahydro-pyrido-pyrimidine derivatives | NOVARTIS AG (CH) | 2014-02-18 | — | — | US | disclosed |
| US-20120065183-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2012-03-15 | — | — | US | disclosed |
| CN-100398107-C | Use of IkappaB-kinase inhibitors in pain therapy | AVENTIS PHARMA GMBH (DE) | 2008-07-02 | — | — | CN | disclosed |
| CN-1675196-A | Indole derivatives or benzimidazole derivatives for modulating IKB kinase | AVENTIS PHARMA GMBH (DE) | 2005-09-28 | — | — | CN | disclosed |
| CN-1674899-A | Use of IkappaB-kinase inhibitors in pain therapy | AVENTIS PHARMA GMBH (DE) | 2005-09-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065183-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | NOTUM 2780/4885TSHR 1204/4885MAPT 2283/4885 |
| US-20140051676-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | NOTUM 3296/4885TSHR 1712/4885MAPT 2602/4885 |
| US-20160052912-A1 | DIAMINOHETEROARYL SUBSTITUTED INDAZOLES | BUB1, BUB1B, BUB3 | NOTUM 3324/4885TSHR 3830/4885MAPT 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.